[go: up one dir, main page]

MX2019001280A - NOVEL PHARMACEUTICAL COMPOSITIONS WITH A MODIFIED BETA-DEFENSIN FUSION PEPTIDE HßD3-M AND COMMERCIAL ANTIBIOTICS FOR USE IN THE TREATMENT OF INFECTIONS WITH PATHOGENIC BACTERIA. - Google Patents

NOVEL PHARMACEUTICAL COMPOSITIONS WITH A MODIFIED BETA-DEFENSIN FUSION PEPTIDE HßD3-M AND COMMERCIAL ANTIBIOTICS FOR USE IN THE TREATMENT OF INFECTIONS WITH PATHOGENIC BACTERIA.

Info

Publication number
MX2019001280A
MX2019001280A MX2019001280A MX2019001280A MX2019001280A MX 2019001280 A MX2019001280 A MX 2019001280A MX 2019001280 A MX2019001280 A MX 2019001280A MX 2019001280 A MX2019001280 A MX 2019001280A MX 2019001280 A MX2019001280 A MX 2019001280A
Authority
MX
Mexico
Prior art keywords
antibiotics
hßd3
pathogenic bacteria
fusion peptide
pharmaceutical compositions
Prior art date
Application number
MX2019001280A
Other languages
Spanish (es)
Inventor
Burguete Gerardo Alfonso Corzo
Yañez Alondra Gabriela Callejas
VALDEZ María CORDERO
Lavín García Lascurain Luis Martínez
VALENCIA Marco Antonio IBARRA
SOSA Iván ARENAS
Original Assignee
Univ Mexico Nac Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nac Autonoma filed Critical Univ Mexico Nac Autonoma
Priority to MX2019001280A priority Critical patent/MX2019001280A/en
Publication of MX2019001280A publication Critical patent/MX2019001280A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel pharmaceutical compositions comprising a fusion peptide of a modified beta-defensing HßD3-M with additive or synergistic antibiotic activity when suitably combined with commercially available antibiotics. Said peptides can be synthesized chemically or by recombinant DNA techniques. Also, it comprises their use as antibiotics for the control of bacterial infections, particularly against resistant strains of P. Aeruginosa and S. Aureus, solving the technical problem of resistance to antibiotics that said pathogenic bacteria present. Further, it discloses the identification of Pharmaceutical mixtures or compositions suitable as pharmaceutical formulations for use in treating diseases caused by bacterial infections in mammals.
MX2019001280A 2019-01-30 2019-01-30 NOVEL PHARMACEUTICAL COMPOSITIONS WITH A MODIFIED BETA-DEFENSIN FUSION PEPTIDE HßD3-M AND COMMERCIAL ANTIBIOTICS FOR USE IN THE TREATMENT OF INFECTIONS WITH PATHOGENIC BACTERIA. MX2019001280A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2019001280A MX2019001280A (en) 2019-01-30 2019-01-30 NOVEL PHARMACEUTICAL COMPOSITIONS WITH A MODIFIED BETA-DEFENSIN FUSION PEPTIDE HßD3-M AND COMMERCIAL ANTIBIOTICS FOR USE IN THE TREATMENT OF INFECTIONS WITH PATHOGENIC BACTERIA.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019001280A MX2019001280A (en) 2019-01-30 2019-01-30 NOVEL PHARMACEUTICAL COMPOSITIONS WITH A MODIFIED BETA-DEFENSIN FUSION PEPTIDE HßD3-M AND COMMERCIAL ANTIBIOTICS FOR USE IN THE TREATMENT OF INFECTIONS WITH PATHOGENIC BACTERIA.

Publications (1)

Publication Number Publication Date
MX2019001280A true MX2019001280A (en) 2020-07-31

Family

ID=83507362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001280A MX2019001280A (en) 2019-01-30 2019-01-30 NOVEL PHARMACEUTICAL COMPOSITIONS WITH A MODIFIED BETA-DEFENSIN FUSION PEPTIDE HßD3-M AND COMMERCIAL ANTIBIOTICS FOR USE IN THE TREATMENT OF INFECTIONS WITH PATHOGENIC BACTERIA.

Country Status (1)

Country Link
MX (1) MX2019001280A (en)

Similar Documents

Publication Publication Date Title
RU2018107249A (en) APPLICATION OF LYSINE TO RESTORE / INCREASE ANTIBACTERIAL ACTIVITY OF ANTIBIOTICS IN THE PRESENCE OF A PULMONARY SURFACTANT WHICH INHIBITS THE INDICATED ANTIBIOTICS
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
WO2012036580A3 (en) Antibacterial phage, phage peptides and methods of use thereof
ES2682670T3 (en) Streptococcus bacteriophage lysines for the detection and treatment of gram positive bacteria
RU2014149351A (en) BACTERIOPHAGE LYSINE COMBINATIONS AND ANTIBIOTICS AGAINST GRAM-POSITIVE BACTERIA
WO2018115140A3 (en) Virulence attenuated bacteria based protein delivery
MX369056B (en) PREVENTION, INTERRUPTION AND TREATMENT OF BIOFILM WITH BACTERIOPHAGUS LYSINE.
MX2020006098A (en) Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa.
WO2010141760A3 (en) Antimicrobial peptides
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
WO2018155813A3 (en) Novel antibacterial protein efal-2 having bacteriolytic ability with respect to enterococcus faecium
WO2019077634A3 (en) Therapeutic compositions of antimicrobial peptides
WO2008036761A3 (en) Anti-microbial defensin-related peptides and methods of use
CA3010564A1 (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
WO2010041970A3 (en) Antibacterial phage peptides and methods of use thereof
WO2019195714A8 (en) Methods and compositions for treating skin disease with recombinant microorganisms
MX2023015156A (en) Modified antimicrobial peptides.
WO2013041663A3 (en) Modified apidaecin derivatives as antibiotic peptides
DE602005018374D1 (en) ANTIBACTERIAL PEPTIDES AND ANALOGUE THEREOF
WO2019067498A3 (en) Peptide antibiotic complexes and methods of use thereof
HRP20200195T1 (en) Water buffalo derived peptide antibiotic therapies
PH12021552875A1 (en) METHODS AND COMPOSITIONS COMPRISING STAPHYLOCOCCUS PROTEIN A (SpA) VARIANTS
WO2014130655A3 (en) Compositions and methods to inactivate and/or reduce production of microbial toxins
MX2019001280A (en) NOVEL PHARMACEUTICAL COMPOSITIONS WITH A MODIFIED BETA-DEFENSIN FUSION PEPTIDE HßD3-M AND COMMERCIAL ANTIBIOTICS FOR USE IN THE TREATMENT OF INFECTIONS WITH PATHOGENIC BACTERIA.